Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Percheron Therapeutics ( (AU:PER) ) has issued an update.
Percheron Therapeutics has announced the final results of its Phase I clinical trial for HMBD-002. The results of this trial are significant for the company’s operations and may influence its positioning in the pharmaceutical industry, although the inherent risks and uncertainties in drug development are acknowledged.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Average Trading Volume: 3,152,884
Technical Sentiment Signal: Sell
Current Market Cap: A$10.87M
Find detailed analytics on PER stock on TipRanks’ Stock Analysis page.